Alentis Therapeutics

🎄✨ Happy Holidays from Alentis! ✨🎄 As we wrap up 2024, we’re reflecting on a year of remarkable milestones and growth: - Welcoming incredible new colleagues to our team and board. - Advancing our innovative pipeline, including an IND clearance for the first-ever CLDN1 ADC. - Securing an outstanding Series D financing to fuel our mission. We’re immensely grateful to our team, partners, and supporters for making these achievements possible. Here’s to a joyful holiday season and a 2025 filled with exciting breakthroughs and new opportunities! 🚀 Stay tuned—there’s much more to come!   #AlentisTherapeutics #MerryChristmas #Happy2025

Many thanks to Pr. David Jayne from the University of Cambridge for collaborating with us on the review paper that was published in Nephron, a leading peer-reviewed journal in #Nephrology and #KidneyDisease. The article, titled “Exploring the Critical Role of Tight Junction Proteins in Kidney Disease Pathogenesis,” examines the multifaceted roles of tight junction proteins, including Claudin-1, and highlights their contributions to kidney disease mechanisms and their potential for therapeutic development. The full article is freely accessible on #PubMed: https://lnkd.in/e_GGgBVS #AlentisTherapeutics #ReviewArticle #CLDN1 #KidneyFibrosis #Fibrosis #ANCAVasculitis

Our Chief Scientific Officer, Alberto Toso will present at the 1st Claudin-Targeted Therapies Summit held virtually on December 4-5. Great to see so many companies joining the exciting Claudin space! Alberto will present our pipeline of antibody-drug conjugates (#ADC) and antibodies targeting Claudin-1, an extraordinary target that plays a key role in #oncology and #fibrosis. Learn more here: https://lnkd.in/eEPJaTfp #AlentisTherapeutics #Claudin #CLDN1 #CLDN18.2 #CLDN6

Good news! The FDA granted Fast Track designation to ALE.P02, our first-in-class antibody-drug conjugate (ADC) targeting Claudin-1. The designation is granted for the treatment of advanced or metastatic CLDN1+ squamous cell tumors, irrespective of the organ of origin. Watch the video with Stella Augustus, our Head of Regulatory Affairs, on why this designation is remarkable. A Phase 1/2 clinical trial of ALE.P02 is planned to start Q1 2025 in patients with CLDN1+ lung, head and neck, cervical or esophageal squamous cancers. Read the full press release: https://lnkd.in/edVdnbkQ #AlentisTherapeutics #FastTrack #FDA #ADC #CLDN1 #Claudin #Oncology

Geoffrey Teixeira, our SVP Head of Fibrosis will represent Alentis at the Antifibrotic Drug Development Summit #AFDD2024. Geoffrey will give a presentation titled: ‘Examining Anti-Claudin-1 (#CLDN1) Monoclonal Antibodies in Development for Liver, Kidney & Lung Fibrosis as a Novel Mechanism to Reverse Fibrosis’. The conference is held November 19-21 in Boston, MA. More information: www.afdd-summit.com #AlentisTherapeutics #Claudin #Fibrosis #DrugDevelopment

🚀 Proud moment for Alentis! Our Series D financing was featured on the Nasdaq Tower in Times Square, NYC! A huge thank you to everyone who helped make this possible. Stay tuned as we continue advancing our innovative antibody-drug conjugate (ADC) treatments for cancer. Exciting times ahead! Learn more: https://lnkd.in/eBaY24ue #AlentisTherapeutics #ADC #TimesSquare #NYC

We are delighted to announce the successful closing of an oversubscribed Series D financing, raising $181.4M to develop a deep pipeline of CLDN1 targeted medicines for solid tumors. The funding was supported by a syndicate of top-tier biotech investors including OrbiMed as lead and Novo Holdings and JEITO as co-leads as well as substantial contributions from Frazier Life Sciences, Longitude Capital, RA Capital Management, and Catalio Capital Management. This financing is a testament to the transformational potential of CLDN1 targeted medicine in oncology, in particular our first-in-class antibody-drug conjugates (#ADCs) ALE.P02 and ALE.P03. We’re excited to start Phase 1/2 clinical trials for both programs in 2025. Read the full press release: https://lnkd.in/eVSGPG5G We extend our deepest gratitude to our investors for their trust and support. Together we are making a difference 🌍💙 #AlentisTherapeutics #Biotech #Funding #Healthcare #LifeSciences #ADC #CLDN1 #Claudin

We are excited to announce Alentis management is heading to the Jefferies London Healthcare Conference! Representing the company: Roberto Iacone, CEO, Rizwan Velji, CBO, and Jonathan Freve, CFO. We're looking forward to engaging with industry leaders, investors, and partners at this important event. #AlentisTherapeutics #London #Biotech #Partnering #JefferiesHealthcare

Congratulations Vincent Anquetil for your excellent work!

Proud that we were invited to present among the top companies and KOLs in the fibrosis field at the International Conference on Tissue Repair, Regeneration, and Fibrosis! Geoffrey Teixeira, our SVP Head of Fibrosis, will give a presentation titled: ‘Targeting Claudin-1 as a novel therapeutic approach to reverse organ fibrosis’, where he will discuss our clinical-stage mAb lixudebart (ALE.F02) developed for kidney, liver and lung #fibrosis. The conference is held Oct 22-27 in Heraklion, Greece. Find more information on the conference here: https://lnkd.in/eEW7B6Ra #AlentisTherapeutics #Claudin #CLDN1